Xenetic Biosciences报告财年业绩

2026-03-14 03:26

Xenetic Biosciences press release (XBIO): FY Net loss for the year ended December 31, 2025 was approximately $2.7 million, reflecting investment in the Company's most promising scientific programs.
Royalty revenue from the Company's sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries.
Research and development expenses for the year ended December 31, 2025 decreased by approximately $0.2 million, or 7%, to $3.1 million from $3.3 million in the prior year period. Research and development costs for the year ended December 31, 2024 included a $0.7 million impairment charge that did not reoccur in 2025.

More on Xenetic Biosciences